Baseline Characteristics in VISIONARY Trial of Sibeprenlimab | Docwire News
At SCM25, researchers presented baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy (IgAN).
Related Articles
New Study Suggests Champagne May Help Prevent Sudden Cardiac Arrest
Move over apples—champagne might actually help keep the doctor away. A new study finds certain lifestyle additions, including moderate champagne consumption, may lower the risk…
Reduced-Dose Apixaban Anticoagulation Noninferior to Full Dose in Cancer-Associated VTE Prevention | Docwire News
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States:
AbstractBackgroundSudden cardiac arrest (SCA) is the leading cause of death among young competitive athletes during sports and exercise. A detailed analysis of survival outcomes should…
Episode 410: AUA 2025 – BOND-003 Cohort C: Crestimogene in BCG-Unresponsive NMIBC | GU Oncology Now
Dr. Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC.
Novel Trispecific Antibody Offers New Path Forward for Patients With Multiple Myeloma | Blood Cancers Today
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies for patients with relapsed or refractory…
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial
AbstractBackgroundGrowing evidence suggests that reduced activity of the growth hormone (GH)/insulin-like growth factor (IGF)-1 axis is common and associated with poor clinical status and outcome…
Episode 409: AUA 2025 – CREST – BCG +/- Sasanlimab in High-Risk NMIBC | GU Oncology Now
Dr. Neal Shore joins the show to discuss exciting data from the CREST trial at the American Urological Association Annual Meeting.
Second-Line Belantamab Mafodotin in Multiple Myeloma: Will These DREAMMs Become Reality?
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA in multiple myeloma, is likely to regain FDA approval based on the DREAMM-7 and DREAMM-8 trials. In this…
Proposed Changes to Federal Health Agencies Threaten Future Cancer Research Advancements – ASCO
The Association for Clinical Oncology (ASCO) is carefully reviewing the Administration’s Fiscal Year 2026 “skinny” budget proposal, which was released May 2 and contains significant…
Advanced glycation end products and breast cancer risk in a sample of the ORDET cohort – PubMed
IntroductionBreast cancer is the most common cancer among women, and metabolic syndrome (MetS) is a risk factor for breast cancer, especially postmenopausal breast cancer. We…